Skip to main content
Phase I study of vemurafenib in children with recurrent or progressive BRAFV600E mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002).
Glycan microarray reveal induced IgGs repertoire shift against a dietary carbohydrate in response to rabbit anti-human thymocyte therapy.
Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors.
Acquired resistance to BRAF inhibition in BRAFV600E mutant gliomas.
GBM heterogeneity as a function of variable epidermal growth factor receptor variant III activity.
IKK/NF-?B signaling contributes to glioblastoma stem cell maintenance.
Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors.
EGFR blockade prevents glioma escape from BRAFV600E targeted therapy.